143 results
8-K
ORKA
Oruka Therapeutics Inc.
5 Sep 24
Oruka Therapeutics Announces Closing of Merger with ARCA biopharma and Previously Announced Private Placement of $275 Million
5:18pm
VYNE Therapeutics Inc. (Nasdaq: VYNE), from September 2017 to March 2020, where she was responsible for leading all non-R&D functions, including
425
ORKA
Oruka Therapeutics Inc.
9 Aug 24
Business combination disclosure
8:35am
Sandler SVP, Operations Joe Senn SVP, Nonclinical R&D Lawrence Klein CEO Arjun Agarwal SVP, Finance Paul Quinlan General Counsel Andrew Blauvelt Chair
425
ORKA
Oruka Therapeutics Inc.
1 Aug 24
Business combination disclosure
4:30pm
and the Merger, including legal, accounting and advisory expenses and other related charges.
Research and development (R&D) expenses were $0.1 million … for the quarter ended June 30, 2024, compared to $0.3 million for the corresponding period in 2023. Of the $0.2 million decrease in R&D expenses in the second
8-K
EX-99.1
ORKA
Oruka Therapeutics Inc.
1 Aug 24
ARCA biopharma Announces Second Quarter 2024 Financial Results and Provides Corporate Update
4:25pm
and advisory expenses and other related charges.
Research and development (R&D) expenses were $0.1 million for the quarter ended June 30, 2024 … , compared to $0.3 million for the corresponding period in 2023. Of the $0.2 million decrease in R&D expenses in the second quarter of 2024 as compared
424B3
ORKA
Oruka Therapeutics Inc.
1 Aug 24
Prospectus supplement
4:10pm
costs in the foreseeable future.
Research and Development Expenses
Research and development (“R&D”) expense is comprised primarily of personnel costs … , clinical development, manufacturing process development, and regulatory activities and costs.
R&D expense for the three months ended June 30, 2024
425
8uib7yez7lze5a zv
6 Jun 24
Business combination disclosure
4:45pm
425
is5bn9v5b6ev tb
25 Apr 24
Business combination disclosure
4:27pm
8-K
EX-99.1
f7dtop15cntamdwnjs
25 Apr 24
ARCA biopharma Announces First Quarter 2024 Financial Results and Provides Corporate Update
4:25pm
8-K
EX-99.1
3sj0aqz imld8gq5
1 Feb 24
ARCA biopharma Announces 2023 Financial Results
4:39pm
8-K
EX-99.1
510p02rg4wts bd9na
18 Oct 23
ARCA biopharma Announces Third Quarter 2023 Financial Results
4:35pm
8-K
EX-99.1
15wr4s
21 Jul 23
ARCA biopharma Announces Second Quarter 2023 Financial Results
4:35pm
8-K
EX-99.1
1qef5akw rt
24 Apr 23
ARCA biopharma Announces First Quarter 2023 Financial Results
4:35pm
8-K
EX-99.1
fxgb3po
28 Oct 22
ARCA biopharma Announces Third Quarter 2022 Financial Results
4:25pm